Why the study?
Do PCC, aPCC, rFVIIa, or a specific antidote (aDabi-Fab) reverse the anticoagulant effects of dabigatran ex-vivo in a porcine trauma model?
Do PCC, aPCC, rFVIIa, or a specific antidote (aDabi-Fab) reverse the anticoagulant effects of dabigatran ex-vivo in a porcine trauma model?
In a preclinical porcine trauma model, a specific dabigatran antidote fully reversed dabigatran-induced anticoagulation, whereas PCC and aPCC provided partial reversal and rFVIIa was ineffective.
Answers are grounded in this paper and cite their sources.
Supports specific dabigatran antidote development; hypothesis-generating in porcine model, requires human validation before practice change.
INTRODUCTION: New oral anticoagulants are effective alternatives to warfarin. However, no specific reversal agents are available for life-threatening bleeding or emergency surgery. Using a porcine model of trauma, this study assessed the ability of prothrombin complex concentrate (PCC), activated PCC (aPCC), recombinant FVIIa (rFVIIa) and a specific antidote to dabigatran (aDabi-Fab) to reverse the anticoagulant effects of dabigatran. METHODS: Dabigatran etexilate (DE) was given orally for 3 days (30 mg/kg bid) and intravenously on day 4 to achieve consistent, supratherapeutic concentrations of dabigatran. Blood samples were collected at baseline, after oral DE, after intravenous dabigatran, and 60 minutes post-injury. PCC (30 and 60 U/kg), aPCC (30 and 60 U/kg), rFVIIa (90 and 180 μg/kg) and antidote (60 and 120 mg/kg) were added to blood samples ex-vivo. Coagulation was assessed by thromboelastometry, global coagulation assays and diluted thrombin time. RESULTS: Plasma concentrations of dabigatran were 380 ± 106 ng/ml and 1423 ± 432 ng/ml after oral and intravenous administration, respectively, and all coagulation parameters were affected by dabigatran. Both PCCs and aDabi-Fab, but not rFVIIa, reversed the effects of dabigatran on thromboelastometry parameters and prothrombin time. In contrast, aPTT was only normalised by aDabi-Fab. Plasma concentration (activity) of dabigatran remained elevated after PCC and rFVIIa therapy, but was not measureable after aDabi-Fab. CONCLUSION: In conclusion, PCC and aPCC were effective in reducing the anticoagulant effects of dabigatran under different conditions, while aDabi-Fab fully corrected all coagulation measures and decreased the plasma concentration of dabigatran below the limit of detection. No significant effects were observed with rFVIIa.
No takes yet. Share an insight, caveat, or question.
Grottke et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: